Through its acquisition of G-CON, Summa Equity enters the rapidly growing biopharmaceutical manufacturing market, including cell and gene therapy manufacturing.
STOCKHOLM, July 20, 2021 /PRNewswire/ -- Summa Equity Fund II ("Summa") has acquired a majority stake in G-CON, a leading US-based manufacturer of